MELA Sciences (MELA) Makes Several Key Board Appointees

MELA Sciences (Nasdaq: MELA) has appointed several new directors to serve on its Board -- Robert Coradini, Mark Fabiani, John Goddard, James Noble, and David Stone.

Robert Coradini: Former President of several Johnson & Johnson Companies (NYSE: JNJ), including Cordis Endovascular, LifeScan and Cardiovations, President of New Ventures for J&J Consumer Group, and head of business development for J&J Medical Device & Diagnostics Group.

Mark Fabiani: Formerly Special Counsel to President Clinton, Deputy Campaign Manager for Vice President Al Gore, and Deputy Assistant Attorney General at the Justice Department. Mr. Fabiani is Principal of Fabiani and Lehane, a specialty communications and advisory firm.

John Goddard: Former Chief Financial Officer AstraZeneca's US operations and Head of Strategic Planning and Business Development of AstraZeneca PLC. (NYSE: AZN).

David K. Stone: Founder and Managing Director of Liberty Tree Advisors, LLC, a former Managing Director of Research at Cowen & Company and former Managing Director and Partner at Flagship Ventures.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
• Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
• Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)